NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02768337 2024-01-31
CamBMT1
Cambridge University Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT01861223 2014-02-25
Afatinib Plus Nimotuzumb for NSCLC
Samsung Medical Center
Phase 1/2 Unknown